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Abstract: 
The physiological process of bone healing takes place in three sequential stages: inflammation, 
repair and remodelling. Multipotential stromal cells (MSCs) are the key progenitor cells for 
osteoblasts and chondrocytes and are also imbued with immunomodulatory capabilities.  
Although MSCs are well known to be involved in osteogenesis during the later stages of repair, 
their role during the inflammatory phase and precise interactions with immune cells remain 
poorly understood.  This chapter describes the current knowledge on cellular interactions 
during the bone repair as well as cytokines and growth factors mediating these processes.  The 
roles of emerging innate immune cell populations, innate lymphoid cells are also discussed.  
Based on this current knowledge, we conclude that in addition to their differentiation during 
later bone repair stages, MSCs are likely to have a substantial involvement in the initial stage 
of bone healing by controlling the fate of inflammation. An improved understanding of 
complex cell interactions during bone repair has broad implications on optimising the treatment 
of the fracture complications including non-union. 
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I. Introduction 
Human bone has a unique structure formed of outer dense layer of cortical bone responsible 
for the weight bearing function.  The outer bone is covered by the periosteum that has a 
contributing role in the osteogenesis and the removal of the periosteum delays significantly the 
bone repair (1).  The inner part of the bone is a mesh-like cancellous bone containing bone 
marrow (BM) where various cell types including multipotential stromal cells (MSCs) exist (2).  
The first description of MSCs was as colony-forming unit fibroblasts with capability to 
generate a new bone in ectopic sites (3).  Later on, they were renamed as mesenchymal stem 
cells (4).  According to the International Society of Cell Therapy (ISCT), MSCs are defined in 
vitro as plastic adherent cells, which do not express hematopoietic lineage markers CD45, 
CD34, CD14 or CD11b, CD79 alpha, CD19 and HLA-DR, but they express surface molecules 
CD90, CD73, CD105. Thirdly, MSCs are able to differentiate into osteoblasts, adipoblasts and 
chondroblasts (5).   
There are many tissues where MSCs can exist in skeleton including the periosteum, 
bone, BM, muscles, tendons, ligaments, and adipose tissue (6).  In animal models, MSCs can 
migrate from BM into blood then circulate and home to the injury site where they can be active 
in repairing tissues (7).   The most common and best-characterised source of MSCs is BM. The 
surface molecule CD271 is currently considered as a distinctive and selective marker for human 
BM and bone MSCs (8, 9).  Interestingly, the periosteum contains MSCs with chondrogenic 
and osteogenic potential that is comparable to BM MSCs (10). Furthermore, periosteal MSCs 
are higher in quantity relative to BM MSCs in canine models (11) but it is unknown if periosteal 
MSCs are similarly abundant in human.   
The proliferation of MSCs is closely linked to their differentiation function.  Rapidly 
growing MSCs have superior differentiation abilities compared to slower proliferating MSCs 
(12). In addition to mesenchymal tissue differentiation, MSCs can display immunomodulatory 
functions, mostly suppression of the proliferation and functions of different immune cells (13).  
Critically, MSCs need to be primed by inflammatory cytokines to play their 
immunomodulatory role (14).  With the advancement of the examination of the surface 
phenotype and the functional characterisation of MSCs from multiple tissue sources, the 
importance of MSCs as key cells in bone healing becomes better understood. 
 Although the bone healing is a successive process, its phases are overlapping to some-
extent, inflammation, repair phase including chondrogenesis followed by ossification then 
finally remodelling phase.  When a fracture or bone loss occurs, the injury-driven rupture of 
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blood vessels and vasodilation causes an exudation of plasma into the surrounding tissues.  
Plasma-derived fibrinogen is converted into fibrin forming a haematoma which traps various 
inflammatory cells and MSCs (15).  The function of inflammation is the clearance of the 
damaged tissue and the initiation of the repair by providing the needed cells and the appropriate 
cytokines and growth factors (16).  Subsequent to the inflammatory phase, a repair phase starts 
with differentiation of MSCs into chondroblasts, which proliferate and differentiate, forming a 
cartilaginous thickened structure called soft callus.  Then chondroblasts undergo hypertrophy 
and begin to deposit mineralised matrix and soft callus is converted into new bone (hard) callus.  
This process is known as endochondral ossification leading to the formation of irregularly 
arranged (woven) bone.  During this phase new blood vessels are formed in a process called 
angiogenesis.  The final phase includes remodelling of woven bone into lamellar bone i.e. 
normally aligned bone (17-20).   
 Intramembranous repair involves a direct differentiation of MSCs into osteoblasts and 
it usually happens when broken bone edges are perfectly aligned (direct or primary healing) 
(17).  In addition to MSCs, bone cells including osteoclasts and osteoblasts also play important 
roles in bone healing.   Osteoclasts are giant multinucleated cells originated from monocyte 
lineage cells and express tartrate-resistant acid phosphatase.   The main function of osteoclasts 
is bone resorption through release of the enzymes and other molecules, which degrade the bone 
matrix (21).  Osteoblasts are bone-forming cells originated from MSC-derived progenitors.  
The balance between the functions of these bone cells and immune cells, helps to maintain the 
normal quantity and the function of the regenerating bone and is critical to determine the fate 
of the healing process (22).  In this chapter, the role of various immune cells, cytokines, bone 
cells and MSCs and their interactions during different phases of the bone healing in health and 
as well as in exaggerated inflammatory milieu are reviewed (Figure 1, 2 and 3, Table 1 and 2).   
 
II. Inflammatory phase 
Inflammation taking place at the fracture site is caused by the damage of tissues, hypoxic and 
low pH environment.  Inflammatory phase involves several events including recruitment of 
different blood cells and release of various inflammatory chemokines and cytokines (16, 23).  
Immune response is critical for physiological uncomplicated healing of fractured bone.   The 
transfer of immune cells from young mice via BM transplantation into immune-compromised 
mice improves significantly the process of bone repair (24).  Furthermore, immune-
compromised patients such as HIV-infected individuals show delayed or complicated healing 
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of bone fractures (25).  Although different factors could be involved in HIV-related fragility of 
healing bones, immune-related mechanisms have been demonstrated.  For example, serum 
level of both Tumour necrosis factor-Į71)-D) and the TNF receptors are increased in these 
patients in comparison to healthy controls (26).    Cells and molecules of innate and adaptive 
immune systems as well as MSCs are involved in inflammatory phase of bone healing to 
maintain tissue haemostasis through removal of the damaged cells and induction of cartilage 
and bone repair in addition to angiogenesis (27).  The role of different immune cells and MSCs 
as well as other inflammatory soluble factors are discussed below. 
 
i. Neutrophils 
The first cells to be recruited into hematoma at the injury site are neutrophils.  In a rat model 
of tibia fracture, neutrophils were detected at the fracture callus on day 1 and remained for few 
days after the fracture (28).  In association with high-level of chemokine, cytokine-induced 
neutrophil chemoattractant-1 (CINC-1), neutrophils migrate across the endothelium into 
hematoma site (29).  Neutrophils are important to eliminate the microbial infection (30).  The 
functions of neutrophils at the fracture site also include phagocytosis of the damaged cells and 
debris (27).  Although they have short life span, neutrophils play antiseptic role at the fracture 
site, but it remains unknown if they interact with MSCs. 
 
ii. Macrophages and monocytes 
Macrophages are recruited into the fracture site from the periosteum or peripheral blood (31, 
32).  Macrophage-colony stimulating factor (M-CSF), which is known to target mainly 
macrophages (33), is expressed in the fractured bone, peaking during inflammatory phase then 
again when remodelling phase starts (34) indicating an involvement of the macrophages during 
all phases of the repair.  Macrophages and platelets produce bone morphogenetic proteins 
(BMPs), which contribute in organising the shape of the different tissues particularly bone and 
cartilage (35).  BMPs are known to stimulate the proliferation of MSCs and enhance their 
osteogenic differentiation (36).  Another molecule, Oncostatin M is produced by 
monocytes/macrophages and induces osteogenic markers, Core-binding factor alpha 1/runt-
related transcription factor 2 (Cbfa1/Runx2) and alkaline phosphatase (ALP) in MSCs 
enhancing their differentiation into osteoblasts (37, 38).  Additionally, monocyte-derived 
exosomes also increase the bone-forming function of MSCs via the induction of the expression 
of Cbfa1/Runx2 and BMP2 in MSCs (39).  Monocytes activated by interleukin-4 (IL-4) or 
lipopolysaccharide (LPS) elevates the expression level of Cbfa1/Runx2 and ALP by MSCs 
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(40).   Thus interactions between MSCs and macrophages induce the osteogenic ability of 
MSCs preparing for the repair phase.  
 
iii. NK cells 
Natural Killer (NK) cells constitute an important part of innate immune system and are divided 
into two functional subsets; bright CD56 (cytokine producers or regulatory NK cells) and dim 
CD56 (killers).  NK cells can circulate and reach different organs where they become activated 
and function to keep immune haemostasis in different tissues (41).  Up to date, little is known 
about the biological roles of NK cells during the bone healing.  One study has described a high 
expression of interferon-Ȗ,)1-ȖLQ WKHWLVVXHVRIGLDSK\VHDOUHJLRQVRIIUDFWXUHGIHPXULQ
RAG-/- mice model, which lack both T and B lymphocytes (42).  As a major source of IFN-Ȗ
this study has pointed to the importance of NK cells during bone repair.  This role is assumed 
because NK cells produce a major priming cytokine for immunomodulatory function of MSCs, 
IFN-Ȗ(42).  Yet, further research is needed to understand the magnitude of NK cell-dependent 
priming of MSCs.  The inflammatory milieu as well as MSC-NK cell interactions could modify 
activated NK cell functions to increase the production of IFN-Ȗ(43).  NK cells are also major 
source of TNF-ĮZKLFKKDVD FULWLFDO UROH LQERQH UHSDLU 0LFH ODFNLQJ7NF-ĮKDYHEHHQ
shown to have defective bone generation (44, 45).  In addition to priming effects, NK cells 
have been shown to enhance the migration of MSCs through matrigel inserts (46).    
NK cells stimulate the generation of osteoclasts through release of Receptor activator of 
nuclear factor kappa-B ligand (RANKL) (47).  Data from in vitro studies has shown that 
RANKL and TNF-ĮDOVRWULJJHU monocyte differentiation into osteoclasts (48).  This suggests 
that NK cells can indirectly, via effect on osteoclasts, help the removal of debris and damaged 
tissues in physiological bone repair.  In summary, NK cells can induce MSC functions 
including the priming and the migration via their cytokines in addition to their effect on 
osteoclasts all indicate their important contribution into the bone healing. 
 
iv. Innate lymphoid cells  
Innate lymphoid cells (ILCs) are newly characterised immune cells originated from common 
lymphoid progenitor but they lacking lineage markers for T or B lymphocytes (49, 50).  ILCs 
are divided into three functionally diverse subclasses.  NK cells are considered as a subtype of 
ILC1.  ILCs have common receptors for IL-12 and IL-7 but have heterogonous functions with 
distinctive pattern of cytokine profiles (51, 52).  While ILCs 1 secret Th1 cell-like cytokines, 
TNF-ĮDQG,)1-Ȗ(53, 54), ILCs 2 produce IL-4, IL-5, IL-9 and IL-13 similar to Th2 cells (55-
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57).  In contrast, ILCs 3 have similar profile to Th17 as they produce IL-17 in addition to IL-
22 and M-CSF (58).  Interestingly, ILC3 help the regeneration of damaged inflamed intestine, 
thymic and lymphoid tissues via their production of IL-22 (59-61).  Furthermore, ILCs 2 play 
important role in repair against viral-related damaged of bronchial epithelium (62).   
 Compared to their role in epithelial and lymphoid tissues, little is known about the role 
of these innate cells during the bone healing process.  Interestingly, one study showed that IL-
17 putatively produced by ILCs 3 could induce the expression of Cbfa1/Runx2 as well as late 
osteogenic marker, collagen in MSCs (63).  Although this group indicated that Th17 cells could 
induce osteogenesis, a similar effect of ILCs 3 can be proposed, as they are another source of 
IL-17 (63).   Furthermore, it has been shown that following priming with IFN-ȖDQG71)-Į
IL-22 stimulates the migration and the proliferation as well as osteogenic differentiation of 
MSCs in vitro (64).  This all suggest that these innate immune cells probably work during later 
stage of inflammatory phase to prepare MSCs for next phase of the bone repair.  However, 
there is a need to locate and study the functions of these ILCs within healing bone tissues. 
  
v. T and B lymphocytes 
During inflammatory phase, the acquired immune cells, T and B lymphocytes are important in 
bone healing.   In animal models where T and B are depleted, a defect in bone mineralisation 
and delayed healing has been described (65-67).    T and B lymphocytes are recruited at the 
bone fracture site after 3 days of injury and then reduced in numbers with the start of 
cartilaginous callus formation as shown in animal models (63, 68).  RANKL that is made in 
part by activated T lymphocytes in addition to stromal cells and NK cells stimulates osteoclasts 
to remove the dead bone (69, 70).  
Importantly, T lymphocytes are linked to the priming of immunomodulatory function 
of MSCs as T lymphocytes secret TNF-ĮWKHF\WRNLQHWKDWSHDNVGXULQJERWKLQIODPPDWRU\
and repair phases (34).  Additionally, conditioned media from the cultured CD4 T lymphocytes 
but not CD8 T lymphocytes can induce the expression level of both early and late osteogenic 
markers, Cbfa1/Runx2, ALP, osteocalcin and Bone sialoprotein (BSP) by MSCs (71). Th17 
cells are positive inducers of the osteogenic potential of MSCs and IL-17 enhance osteogenic 
markers in MSCs both in vitro and in vivo (63).  Similarly, T regulatory lymphocytes (T reg 
lymphocytes) are also assumed to be involved in bone healing, as they are major source of 
TGF-ȕZKLFKSURPRWH06&SUROLIHration and osteogenesis (72).  Members of TGF-ȕIDPLO\
TGF-ȕ DQG 7*)-ȕ VKRZHG PD[LPDO H[SUHVVLRQ ZKHQ LQIODPPDWLRQ HQGV DQG FDUWLODJH
formation starts, as they play their role as immunosuppressive cytokines thus controlling the 
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inflammation (73).  Altogether, this illustrates how T lymphocytes can enhance the osteogenic 
potential of MSCs in preparation to the next phase of repair.   
There is some conflicting data about the role of B lymphocytes in bone repair.  While 
it has been shown that B lymphocytes enhance osteoclast formation (74); another study showed 
that B lymphocytes suppressed osteoclastogenesis and promoted death of osteoclasts via TGF-
ȕHxpression (75).  Furthermore, in B lymphocyte deficient mice model of tibial injury, B cells 
did not affect osteoblast differentiation or maturation during intramembranous ossification 
(76).  Remaining inconclusive, there is a need for more studies to understand if B lymphocytes 
have other roles during the bone repair via interactions with MSCs.  
 
vi. Multipotential stromal cells 
Source and Recruitment 
Hematoma formed soon after the bone fracture consists of granulation tissue holding various 
cells including MSCs (15, 77).  The origin of these MSCs could be the periosteum, BM or 
vascular endothelium-supporting cells, pericytes (78-80).  Periosteal-derived MSCs have been 
shown to form bone and cartilage with a help of BMP-2 for their differentiation (81).  In cases 
of open fractures where the periosteum is stripped, MSCs can be also derived from adjacent 
muscle tissue (82).  MSCs are recruited into the fracture site under the effect of an inflammatory 
chemokine, Stromal Derived Factor-1 (SDF-1) as revealed in a mouse model of femoral injury 
(83).  By the activation of alpha serine/threonine-protein kinase (AKT) and extracellular-
signal-regulated kinases (ERK) signalling pathways, SDF-1 induces the migration of MSCs 
and the secretion of angiogenic factor, Vascular endothelial growth factor (VEGF) (84) (85).   
SDF-1 is also an important inducer for BMP-2, which activates MSCs and promotes 
osteogenesis (86).   Another cytokine, which mediates the invasion of MSCs into the injury 
site, is TNF-Į WKDW DFWV YLD 1)-țȕ-dependent signalling pathway (87).  The multiplicity of 
sources of MSCs reflects the vitality of these cells in the bone repair. 
 
The early role of MSCs during inflammatory phase  
Although MSCs have been detected in fracture hematoma, their role in early phase of fracture 
repair is not completely clear.  One in vitro study has suggested that MSCs could be involved 
in phagocytosis of dead cells at the fracture site.  This process is associated with an increase of 
the expression of chemokine receptors, CXCR4 and CXCR5 by MSCs helping recruiting more 
MSCs into the injury site (88).  The exposure of T lymphocytes to these phagocytic MSCs 
could increase the expression of RANTES thus recruiting more CD4 T lymphocytes to the 
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injury site.  Furthermore, these MSCs could stimulate the differentiation of Th-17 cells that are 
linked to osteogenesis (88).  Another study has indicated that MSCs could induce the formation 
of osteoclasts with an involvement of IL-6 and M-CSF (89).  In conclusion, MSCs seem to 
help removal of bone debris directly or by enhancing osteoclastogenesis. Additionally, MSCs 
could induce further recruitment of MSCs and T lymphocytes into the fracture site. 
 
Priming of MSCs during early inflammatory stage 
Inflammation-mediated priming of MSCs is critical to complete the bone healing.  IFN-ȖFDQ
activate the proliferation and immunosuppressive function of MSCs via the activation of the 
Kynurenine pathway (90).  Concomitant with IFN-Ȗ71)-ĮRU,/-1 increase the expression of 
adhesion molecules, ICAM-1 and VCAM-1 on MSC surface helping their contact with T 
lymphocytes and causing an augmented MSC-mediated inhibition of T cell proliferation (91).  
It has been shown that TNF-ĮDOVRKHOSVWKHSUROLIHUDWLRQRI06&VDQGWKHLQLWLDOSULPLQJRI
immunosuppressive function of MSCs via NF-țȕ-dependent mechanism (92).  The 
inflammatory cytokine, IL-1 mediates its effect on MSCs via multiple signalling pathways 
including map kinase (MAK), Jun amino-WHUPLQDONLQDVH-1.DQG1)ț-ȕFurthermore, the 
downstream activation mediated by IL-1 controls the production of immunomodulatory 
factors, prostaglandin 2 (PGE2) and IL-8 by MSCs (93).   
 Within inflammatory milieu, the activation of toll-like receptors (TLRs) on the surface 
of MSCs induces MSC migration, differentiation, proliferation and production of indoleamine 
2, 3-dioxygenase (IDO) and PGE2.  The VWLPXODWLRQRI7/5DFWLYDWHV0$3NLQDVH1)ț-ȕDQG
PI3 kinase signalling pathways (94).  Recently, IL-17 was added to the list of priming factors 
that induce MSC immunomodulatory effect.  IL-17 can induce the production of inducible 
nitric oxide synthase (iNOS) by MSCs as tested in vitro and in vivo (95).   
 In contrast to these priming cytokines, TGF-ȕFDQDFWDVa counterbalancing cytokine 
to decrease the immunosuppressive effect of MSCs. Uniquely, TGF-ȕ DIIHFWV ERWK
immunomodulatory and repair functions of MSCs (96).  One mechanism by which TGF-ȕ
affects MSCs immunomodulatory function is the decrease of iNOS expression in SMAD3-
dependent manner (97).  Similarly, immunosuppressive cytokine, IL-10 abrogates the 
inhibitory effect of MSCs on the proliferation of CD4 and CD8 T lymphocytes (98).  However 
the role of these counteracting cytokines during the inflammatory phase of bone repair is 
probably less evident compared to MSC priming cytokines.  The expression levels of TGF-ȕ
and 3 are increased during cartilaginous callus formation to help differentiation of MSCs (73).   
In conclusion, MSC priming and counteracting cytokines are likely to work synergistically to 
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prime MSCs for their immunomodulatory effects towards the transition to the repair stage of 
bone healing. 
 
The late role of MSCs during inflammatory phase; immunomodulation  
The regulation of immune response within the fracture environment is critical to reduce the 
tissue damage, inhibit fibrosis supporting the bone regeneration (27, 34).  This important role 
of MSCs controlling inflammatory phase helps the transition into the next stage of bone healing 
process (99).  The discovery of an ability of MSCs to regulate immune systems was made in 
late 1990s/early 2000s by the observation that MSCs suppress the proliferation of T 
lymphocytes in vitro and in vivo, indicating an additional function of MSCs (100, 101).  The 
subsequent studies have proven that only inflammatory-primed MSCs can mediate 
immunomodulation of both innate and adaptive immune responses.  The effect of MSCs on IL-
12 or IL-15 activated NK cells includes the suppression of their proliferation, killing and 
secretory functions (102, 103).  The differentiation of T lymphocytes into Th1 and Th17 
subsets can be suppressed by MSCs, however MSCs promote the differentiation of T reg 
lymphocytes (104).  Additionally, MSCs can induce dendritic cells to trigger T reg generation 
via the production of IL-10 by these dendritic cells (105).  Furthermore, MSCs induce the 
apoptosis of T lymphocytes that trigger macrophages to secrete TGF-ȕLQGXFLQJWKHH[SUHVVLRQ
of T reg lymphocytes (106).  Moreover, MSCs have the ability to suppress the function and the 
migration of B lymphocytes via the down-regulation of the chemokine receptors expression; 
CXCR4, CXCR5 and CCR7 on the surface of B lymphocytes (107).   Overall, this indicates 
that MSCs interact with both innate and adaptive immune cells controlling whole inflammatory 
response. 
The mechanisms by which MSCs exert their immunomodulatory effects are mainly 
related to soluble factors.  The soluble immunomodulatory molecules include TGF-ȕ ,'2
iNOS, PGE2, IL-1 receptor antagonist and Tumor necrosis factor-inducible gene 6  (TSG6) 
(108-111).  The use of these different players by MSCs varies according to host species, tissue 
type or priming microenvironment of MSCs (112).  For example, mice MSCs mainly use nitric 
oxide (NO) to modulate immune responses, but IDO is the main player for human MSCs (112).  
In summary, MSCs exert a negative feedback loop to control the inflammation at the fracture 
site. 
 
The summary of inflammatory phase  
 11 
Under the normal condition, inflammatory phase is important initial phase of the bone healing 
(Figure 3).  Neutrophils are the first cells to arrive at the fracture site preventing sepsis.  NK 
cells, TNF-ĮLQDGGLWLRQWR6')-1 help to recruit MSCs.  MSCs directly and via the activation 
of osteoclasts help the removal of the dead cells and debris.  Other immune cells, B and T 
lymphocytes also stimulate the formation of osteoclasts.   Inflammatory cytokines and growth 
factors enhance the proliferation of MSCs as well as priming of MSCs to exert their 
immunomodulatory effects.  As a negative feedback mechanism, primed MSCs then are able 
to suppress the inflammatory responses and help to start the repair phase of bone healing.  
Nevertheless, the effects of some inflammatory cells continue to play their roles during the 
repair phase (Figure 1 and 2).  
 
III. Repair phase  
The repair phase includes the formation of cartilaginous callus in the secondary bone healing 
(endochondral ossification) from the enlarging cartilaginous tissue patches filling the bone 
defect site (113).  On the other hand, the primary bone healing involves the formation of hard 
or bone callus that happens in the absence of cartilaginous callus  (intramembranous 
ossification) (114).  The endochondral ossification is the most common healing type and 
includes the degradation of cartilaginous callus, which then is replaced by the bone callus in 
association with the formation of new blood vasculature.  The role of MSCs and immune cells 
as well as soluble mediators is discussed below. 
 
i. MSCs 
During the repair phase, MSCs proliferate and differentiate into chondroblasts that mature into 
chondrocytes, which deposit cartilaginous matrix (115).  Chondrocytes mature and deposit 
calcium granules into matrix where they precipitate with phosphatase forming apatite crystals 
under hypoxic conditions.  During these events and while a mechanically rigid bone callus is 
forming, a high expression of osteogenic markers, procollagen-I, osteocalcin, ALP and 
osteonectin becomes evident (17, 116). 
The second role for MSCs during this stage includes the production of VEGF under 
control of Cbfa1/ Runx2 transcription factor (117).  BM MSCs express angiogenic factors 
VEGF and angiopoietin-1 (118).  Thus, MSCs are considered the key cells initiating this phase 
by chondrogenic differentiation as well as induction of angiogenesis.  
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ii. Macrophages 
Macrophages are known to be involved in the intramembranous ossification during the repair 
phase (31, 32).  Macrophages also participate in the bone repair via the induction of 
angiogenesis.  A significant decrease in macrophages in CCR2-/- mice was associated with 
impaired vascularisation and delayed formation of callus (31).  Macrophages are present in 
invading vessels during the ossification of mouse long bones (119). 
Later during this phase, macrophages can efficiently secrete matrix metalloproteinases 
(MMPs) to break the cartilage matrix (120, 121).   MMP-9 and MMP-13 have important 
contribution during soft-to-hard callus conversion (122-124).  Matrix metalloproteinases and 
their inhibitors help the conversion of collagen II to type I; and the disturbances in the 
regulation of these enzymes are connected to the fracture non-union (125).  In a mouse model 
of tibia fracture, both resident macrophages and inflammatory circulating macrophages were 
shown to be vital for the deposition of collagen type I (126).  Furthermore, it has been shown 
that the gene expression of macrophage macrosialin protein is positively associated with the 
expression of collagen in fractures (127).  In summary, macrophages are active during whole 
repair phase working synergistically with MSCs to help forming of collagen matrix and 
formation of new blood vessels. 
 
iii. T and B lymphocytes 
Although they disappear at the end of inflammatory phase and during formation of callus, T 
and B lymphocytes reappear during the mineralisation of cartilaginous callus and have been 
detected in a close contact with osteoblasts and osteoclasts (128).  Both types of adaptive 
immune cells are recruited into newly forming hard callus presumably via new blood vessels 
to produce more TNF-Į WKH F\WRNLQH UHVSRQVLEOH IRU the death of mature chondrocytes. 
Additionally, TNF-Į VWLPXODWHV WKH PDWXUDWLRQ RI RVWHREODVWV DQG RVWHRFODVWV KHOSLQJ WKH
conversion from cartilage into bone (44, 45).   Overall, T and B lymphocytes have a role in the 
late stage of bone healing helping the transition of cartilaginous callus into bone callus.  This 
role seems to be mediated via TNF-ĮWRUHJXODWHWKHIXQFWLRQRIRVWHREODVWVDQGRVWHRclasts. 
 
iv. Growth factors and cytokines 
Different growth factors including, platelet-derived growth factor (PDGF), TGF-ȕ,QVXOLQ-like 
growth Factor  (IGF) and fibroblast growth factor-1 (FGF-1) promote the proliferation and the 
differentiation of MSCs into chondrocytes (129) (114).  Similarly, BMPs-2, 4 and 7 induce the 
differentiation and proliferation of MSCs (130).  Furthermore, BMPs stimulate the 
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chondrocytes to secret extracellular matrix proteins such as collagen type II (36).  The 
importance of these factors has been established and it has been shown that the gene expression 
levels of BMPs is significantly lower in the sheep model of delayed bone union compared to 
controls (131).  Furthermore, the depletion of BMPs causes severe defects in the bone 
formation as seen in animal models, whereas the treatment with recombinant BMPs improves 
the fracture repair (132-134).  This indicates that multiple growth factors help chondrogenesis 
at the start of the repair phase. 
The bone fracture needs a good vasculature.  Angiopoitein-1 and -2 proteins are 
expressed early promoting the vascularisation from periosteal capillaries (135). VEGF is 
another key factor in angiogenesis and it is produced in a large quantity from MSCs and 
differentiated chondrocytes converting avascular soft callus into vascularised bone callus.  For 
this process to be completed, the death of chondrocytes and the breakdown of cartilaginous 
callus are happened in TNF-Į-dependent mechanism (136).  Importantly, TNF-ĮVLJQDOOLQJLQ
chondrocytes increases MMPs and angiopoietin coordinating the expression of the regulators 
of endothelial cell survival and modulators of cartilaginous destruction, the MMPs (135). In 
summary, the correct balance between growth factors and cytokines produced by endothelial 
cells and chondrocytes is essential (137) for the transition of cartilaginous callus into 
vascularised bone callus helping the physiological bone repair.  
Interestingly, IL-17 can suppress chondrogenic differentiation of MSCs via down-
regulate the expression of key chondrogenesis transcriptional factor, SRY-box 9 (SOX9) and 
its activator cAMP-dependent protein kinase (PKA) (138).  Nam et al., have reported that an 
exposure of the osteoblasts to IL-17 increases the gene expression of collagen, osteocalcin and 
bone sialoprotein indicating enhanced maturation of osteoblasts (63).  This together shows that 
Th17 cells constitute an important contributing factor into the transition of chondrogenesis into 
osteogenesis. 
 
The summary of the repair phase  
 MSCs and other immune cells are involved in this stage (Figure 1 and 2).  MSCs differentiate 
into chondroblasts developing cartilaginous callus, which then mature into chondrocytes, 
which help the mineralisation of cartilaginous matrix forming bone callus. The growth factors 
help the proliferation and the differentiation of MSCs as well as the maturation of 
chondrocytes.  Additionally, macrophages help the deposition of cartilaginous matrix.  
Angiogenesis starts in this phase with a help of MSCs, macrophages and growth factors.  Other 
immune cells, T and B lymphocytes reappear late in this phase during the mineralisation of 
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cartilaginous callus helping the transition into bone callus aided by inflammatory cytokines 
TNF-ĮDQG,/-17. 
 
IV. Remodelling phase 
Remodelling phase includes the reinstating of the normal architecture and the orientation of 
the growing bone to restore its normal function.  This occurs by transforming of irregular 
woven bone callus into lamellar bone within two steps, the resorption of mineralised bone and 
then the formation of new lamellar bone (139, 140).   This process is mainly dependent on the 
balance between osteoblast and osteoclast functions with the stimulation by BMPs (36).  Also 
during this phase, new blood vessel formation is continued with minimal roles for immune and 
other hematopoietic cells. 
 
i. Cells 
The established role for MSCs during the bone healing is the differentiation into osteoblasts at 
later stages of the process (141).  Osteoblast formation is tightly controlled by the influence of 
various growth factors and downstream signalling pathways.  Under the effect of TGF-ȕ%03V
and IGF, MSCs differentiate into osteoblasts (142).   Furthermore, the proliferation and 
osteogenic differentiation of MSCs is regulated via the activation of Wnt/catenin signalling 
pathway (143-145).   Cyclooxygenase 2 (Cox-2) protein that induces the production of pro-
inflammatory protein, PGE2 can also stimulate the differentiation of MSCs into osteoblasts. 
Cox-2 knock out mice show delayed healing of tibia fractures (146).  Furthermore, reduced 
Cox2 expression with aging is associated with a delayed bone repair as shown in a mouse 
model of femoral fracture (147).  MSCs have an inhibitory effect on osteoclast generation from 
monocytes progenitors via mechanism mediated partially by the production of Osteoprotegerin 
(OPG) (148).  This shows how MSCs can control the late stages of the bone remodelling and 
further emphasizes the link between inflammation and osteogenesis.  
Osteoblast progenitors mature into mid-stage of collagen-producing cells before fully 
maturing into osteoblasts, which also produce non-collagenous calcium and phosphate binding 
proteins such as osteocalcin and osteopontin forming mineralised bone (149).  Differentiated 
osteoblasts are involved in the matrix formation in cbfa-1/Runx-2 and Osterix-dependent 
mechanisms causing the formation of new lamellar bone (114, 150).   Osteoclasts are 
responsible for the bone resorption and they create acidic microenvironment to demineralise 
the bone matrix and produce enzymes, which erode the bone.  The functions of osteoblasts are 
 15 
balanced by that of osteoclasts and the disruption in this balance leads to defective bone 
formation.  An increase in osteoclast cell numbers and RANKL have been detected in animal 
model of bone non-union (151). 
It has been demonstrated that Th17 cells can enhance osteoclastogenesis (152).  IL-17 
enhances the differentiation of osteoblasts from MSCs as well as enhances the expression of 
RANKL on MSCs thus promoting osteoclastogenesis when MSCs co-cultured with peripheral 
blood mononuclear cells (PBMCs) (153) thus IL-17 can regulate the bone turnover.  Although 
Th17 cells have not been detected in healing bone during remodelling, they are linked to 
osteoblast and osteoclast generation and function, highlighting their possible role in the final 
stage of the bone healing (154).   Additionally, macrophages are suggested to be involved in 
the remodelling phase by enhancement of the osteoblast activity as well as the progenitors of 
osteoclasts (32).  In total, inflammatory cells control the balance of osteoclasts and osteoblasts, 
which is the main feature of the remodelling phase.   
 
ii. Soluble factors and Cytokines 
The main soluble factors that regulate the process of mineralisation of cartilaginous callus are 
M-CSF, RANKL and OPG.  Although the early peak of RANKL is mainly derived from T 
lymphocytes during the inflammatory stage, its second high expression is evident during the 
repair/remodelling phase (34).    RANKL and M-CSF secreted by osteoblasts work to enhance 
the survival and the activity of osteoclasts (155, 156).    
Additionally, a second elevation of pro-inflammatory cytokines, IL-6 and TNF-ĮKDV
been shown to happen later as the mineralised callus is remodelled into lamellar bone.  These 
cytokines that are increased later on healing, are expressed by MSCs and osteoblasts (34).   
Overall, certain cytokines and soluble proteins are released by active osteoblasts then these 
factors work to induce the generation of osteoclasts thus controlling bone remodelling. 
 
The summary of remodelling phase of bone healing 
Bone cells, MSCs as well as certain immune cells are the main players during this phase (Figure 
1 and 2). During this phase, the hard callus formed of irregular woven bone is transformed into 
lamellar regular bone via maintaining the equilibrium between the activity of osteoblasts and 
osteoclasts.  Controlling these processes, MSCs differentiate into osteoblasts and can promote 
osteoclastogenesis.  Th17 and macrophages regulate the balance of osteoblast and osteoclast 
functions.  Growth factors as well as cytokines, which produced by osteoblasts, induce the 
generation and the survival of osteoclasts. 
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V. Intramembranous healing 
Intramembranous healing is characterised by the direct differentiation of MSCs into osteoblasts 
during the repair phase.  Previous evidence has shown that certain immune cells are involved 
in this type of healing.  Bone-lining resident macrophages contribute to the intramembranous 
bone healing as shown in mouse tibial fracture model (126).  Furthermore, the effect of T 
lymphocytes seems to be extended to prepare the osteoblasts for the proliferative phase of the 
bone repair.  It has been reported that lack of T lymphocytes in RAG-/- mice shows delayed 
maturation of osteoblasts and prolonged repair phase that further delay the remodelling phase 
(63).  BMPs are essential for the proliferation of MSCs and the production of Alkaline 
phosphatase from MSCs and osteoblasts favouring bone formation (157, 158).  BMP-3, BMP-
4, BMP-7, and BMP-8 are strictly expressed when the osteoblastic recruitment is most active.  
BMPs transduce their signal through SMAD activation and in conjunction with other signalling 
pathways such as Notch pathway (159-161).  These findings further demonstrate the strong 
link between the bone healing and immune response with a help of growth factors. 
 
VI. MSC-immune cell interactions; implication in defective bone healing 
Complications such as delayed or non-union of bone fractures could be related to systemic 
inflammatory diseases or fracture-related reasons including sepsis, severe soft tissue damage 
and multiple fractures (162).    MSCs can be detected within non-union tissues but they have 
an impaired function including increased their senescence (163).  Additionally, it has been 
demonstrated that the number and the proliferative capacity of BM MSCs can be impaired in 
patients with non-union fractures compared to healthy controls (164, 165).  Furthermore, the 
osteogenic activity is lower compared to BM MSCs (166).  However, these non-union MSCs 
seem to retain their osteogenic differentiation when activated in vitro (165, 167).  Additionally, 
these non-union MSCs can regain a full capacity of osteogenesis if treated with BMP-2 (168).  
Although, it is unknown if the changes in MSC number and function are reasons or results of 
non-union, injecting autologous BM MSCs into non-union site is still widely used in therapy 
(169).  Additionally, this indicates that the defect of non-union MSCs is related to 
microenvironment rather than being an intrinsic fault.  Immune response is linked to bone 
haemostasis due to the direct effects of immune cells on osteoclasts and osteoblasts.  Chronic 
inflammatory disorders due to systemic or local disease are always associated with bone 
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pathology.  The effects of uncontrolled inflammation including cells and cytokines are 
reviewed below. 
 
i. Neutrophils 
A systemic activation of neutrophils using oxygen free radicals leads to a defective healing of 
bone fracture as shown in rodents (170).  Additionally, an induced neutropenia in animal 
models of bone defects shows an enhanced osteogenic repair (171).  Although it is not clear if 
neutrophils interact with MSCS, an excess activation of neutrophils has a negative effect on 
the bone healing. 
 
ii. Macrophages 
As shown in an experimental model of bone fracture in rat, an excessive activation of 
macrophages via systemic injection of lipopolysaccharide can reduce the secretion of BMP-2 
by macrophages and results in a delayed bone healing probably via a negative effect on MSCs 
(157).    Monocytes and particularly those which express a high level of a co-stimulatory 
molecule, Osteoclast-associated receptor (OSCAR) have a greater potential to differentiate into 
osteoclasts via TNF-ĮPHGLDWHGPHFKDQLVPwithin an excessive inflammatory milieu (172).  
This implies an adverse effect of activation of monocytes on the bone repair via their effects 
on both MSCs and osteoclasts.  
 
iii. NK cells 
Within an excessive inflammatory milieu, NK cells could play a role in the pathogenesis of 
delaying bone healing or even bone loss.  Activated NK cells impair the survival and function 
of injected allogeneic or autologous MSCs and subsequently inhibit MSC-dependent 
therapeutic effects (102, 173-176).  NK cells also have a similar role in the pathogenesis of 
inflammation-related bone destruction as shown in a mouse model of arthritis and the depletion 
of NK cells considerably prevents the bone erosion (47).  In conclusion, activated NK cells 
could exert adverse effects on the bone haemostasis. 
 
iv. T and B lymphocytes 
A study comparing the abundance of cytotoxic T lymphocytes within the fracture hematoma 
between healing and non-healing groups of sheep has reported a predominance of T 
lymphocytes in the non-healing group (177).  Moreover, a mouse model of gamma delta T cell 
knock out has been shown an improvement in the bone healing (178).  Interestingly, the 
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uncontrolled stimulation of B and T lymphocytes appear to be important in delayed bone 
healing.  RAG-/- mice, which lack T and B cells, show an enhancement of callus mineralisation 
and bone remodelling and acceleration of the fracture healing (42).  These effects were 
associated with a lower level of pro-inflammatory cytokines, TNF-Į,)1-Ȗ,/-2 and IL-4 at 
local fracture tissues (42).  Activated T lymphocytes are known to release RANKL, which 
enhance osteoclast differentiation from their progenitors and consequently induce the bone 
lysis (156).   Similar to T lymphocytes, B lymphocytes can stimulate the generation of 
osteoclasts as they secret RANKL and specific autoantibodies in case of inflammatory arthritis.  
These autoantibodies have a high binding affinity to the surface of osteoclasts and their 
precursors inducing bone damage (179).  Altogether, the excess activation of these adaptive 
immune cells is harmful for the bone generation. 
In a recent study, a positive correlation has been observed between the delayed bone repair 
and increase of the expression of peripheral blood terminally differentiated CD8+ CD11a+ T 
lymphocytes, which highly produce IFN-ȖDQG71)-Į(180).  Moreover, a depletion of these 
CD8+ T lymphocytes leads to an improvement of bone repair in an osteotomy mouse model 
(180).  In another study, activated Th1 cells or cytotoxic T lymphocytes were found to block 
osteogenic differentiation of MSCs via the effect of IFN-Ȗ (181).  Interestingly, IL-17, which 
is produced by activated Th17 subset of T lymphocytes, has been linked to bone destruction in 
excessive inflammatory milieu (152).  These studies confirm the link between effector T 
lymphocytes and impaired bone healing. 
In contrast to effector subsets of T lymphocytes, T reg lymphocytes have shown no 
suppressive effect on MSC-mediated bone formation probably because of an associated 
suppressive effect on IFN-ȖDQG71)-Į7KLVILQGLQJZDVIXUWKHUFRQILUPHGZKHQLQMHFWHGT 
reg lymphocytes improved the MSC-mediated repair of bone fracture efficiently in an animal 
model (182).  Transplantation of syngeneic MSCs induced T reg response, which was 
associated with a better healing compared to allogeneic MSCs, which induced Th1 response 
marked by the production of IFN-Ȗ(181).  Similarly, infusion of T reg lymphocytes in calvarial 
defect in mice was associated with an enhancement of MSC-mediated bone healing and a 
reduction of the expression of TNF-ĮDQG,)1-Ȗ(181).   
In conclusion, prolonged activation of immune cells inhibits osteogenesis. Depletion of 
haematopoietic cells from human allograft material containing live osteocytes (183) shows no 
adverse immune effects upon graft implantation in vivo (184), but  it is critical to study such 
DOORJUDIW¶VEHKDYLRXUDQG06&IXQFWLRQJHQHUDOO\LQLQIODPPDWRU\PLOLHX.  This will pave the 
way to new therapeutic solutions for non-union bone fractures. 
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v. Cytokines 
Prolonged or uncontrolled inflammatory phase of bone repair could be destructive.  There is a 
link between excess inflammation e.g. in microbial infection, and impaired osteogenesis (185).  
Different inflammation-related cytokines and cells are linked to pathological bone healing.  
TNF-ĮPHGLDWHGFKURQLFLQIODPPDWLRQLQDGLDEHWLFPRXVHPRGHl has been shown to lead to 
the death of regenerating chondrocytes thus impairing the bone formation (186, 187). 
Importantly, TNF-ĮKDVEHHQVKRZQWRVWLPXODWH WKHH[SUHVVLRQRI:QWVLJQDlling pathway 
antagonist, Dickkopf-1 (DKK-1) that has a direct suppressive effect on the differentiation of 
osteoblasts.  Conversely, the suppression of DKK-1 has been shown to activate the Wnt 
signalling pathway and induce the bone growth (188).  DKK-1 seems to suppress the OPG 
production and disturb OPG-RANKL balance, which leads to bone lysis (188).  Another role 
for TNF-Į LV WR VXSSUHVV QHSKURQHFWLQ DQ H[WUDFHOOXODU PDWUL[ SURWHLQ WKDW LQGXFHV WKH
development and growth of osteoblasts (189).  Additionally, TNF-ĮLQGXFHVWKHSURGXFWLRQRI
M-CSF by BM MSCs, which in turn, enhance the expression of the key osteoclastogenic 
cytokine receptor, RANK in the osteoclast progenitors (190).  Targeting TNF-ĮLQWKHVHPRGHOV
reversed these effects and improved bone healing (187).   
In chronic inflammatory milieu, TNF-ĮVXSSUHVVHV the biomarkers of MSC osteogenic 
differentiation via NF-țȕ VLJQDOOLQJ-dependent mechanism (191).  An exposure of mouse 
MSCs to high doses of TNF-ĮDQG,/-1 reduced their osteogenic differentiation as shown by 
suppression of ALP levels compared to controls (192).   Both TNF-ĮDQG,)1-ȖLQKLELWHG06&
osteogenic ability in dose-dependent manner in vitro (180).  Interestingly, an in vitro exposure 
to IFN-ȖDXJPHQWHG71)-Į-mediated apoptosis of BM MSCs and suppressed their osteogenic 
differentiation (182, 191).  The IFN-Ȗ-mediated inhibition of osteogenesis of MSCs was 
associated with increased expression levels of SMAD-6, a negative controller of bone 
differentiation (182).    Additionally, IFN-Ȗ HQKDQFHG WKH IRUPDWLRQ RI RVWHRFODVWV (193).  
Another inflammatory cytokine, IL-6 mediates osteoclastogenesis, and blocking of IL-6 
receptor was shown to protect from bone erosion in mouse model of arthritis (194).   Similarly, 
osteoclast formation was significantly reduced in mouse model of arthritis where IL-1 was 
knocked out indicating that IL-1 has an important role in inflammation-mediated bone lysis 
(195).   
The chronic inflammation and pathological bone formation are associated with 
dysregulation of BMPs and their inhibitors (35). The gene expression of BMP antagonists 
(noggin and follistatin) and certain MMPs, MMP-7 and MMP-12 are higher in non-union 
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tissues compared to that in normal healing callus (196).  In contrast, many genes are inhibited 
in non-union including growth factors IGF-2, FGF-1, TGF-ȕ3'*):QW-induced proteins, 
B-catenin as well as receptors for PGE2 (197). 
In summary, exaggerated or prolonged effect of inflammatory cytokines and cells have 
a negative effect on MSCs by inhibiting their osteogenic ability as well as a stimulatory role 
on osteoclasts leading to defective bone formation (Figure 3).   
 
 
VII. MSC-Immune cell interactions; therapeutic implications to fracture 
repair 
Animal studies and clinical trials, which used MSCs for therapeutic purposes of bone repair, 
indicated that the inflammation status could affect significantly the efficiency of these 
treatments.  The magnitude of inflammation highly influences the immunomodulatory effects 
of MSCs (13).  High dose of IFN-Ȗ RU RWKHU SULPLQJ F\WRNLQHV LV QHHGHG WR LQGXFH WKH
immunosuppressive function of MSCs and consequently the bone healing.  In contrast, weak 
inflammation or low dose of IFN-Ȗ PLJKW QRW EH HQRXJK WR SULPH 06&V IRU
immunosuppressive effect, instead, it could induce the antigen presentation property in MSCs 
and promote the recruitment of immune cells (198, 199).  
Allogeneic MSCs derived from BM, placenta and umbilical cord and implanted under 
the kidney capsule on collagen-based matrix did not form ectopic bone compared to syngeneic 
MSCs in murine recipients (200).  Similarly, cloned MSCs derived from Balb/c mice could not 
promote bone growth in allogeneic mice together with the suppression of osteogenic markers, 
Alkaline phosphatase, cbfa-1/Runx2 and osteocalcin (181).  Additionally, the chondrogenic 
potential of synovial MSCs transplanted into allogeneic rat with anterior meniscus defect was 
impaired relative to autogenic implants (201).  In these conditions, an increase of the local 
expression of NK cells, T and B lymphocytes as well as macrophages was detected (181, 201, 
202).  In addition, a high expression level of allo-specific antibodies was demonstrated in the 
recipient hosts (202).  It has been proposed that Th1 response evident by increase of IFN-ȖZDV
responsible for the suppression of the bone growth (181).  It is likely that the exposure of 
allogeneic MSCs to the activated host immune cells leads to suppression of the functions of 
these MSCs and failure of the therapy. 
 Interestingly, autologous MSCs are susceptible for killing by cytokine-activated NK 
cells.  This killing is related to the low level of HLA class I and to the presence of ligands for 
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NK cell activating receptors on the surface of MSCs (102, 173-176).  Also, the activation of 
NK cells against MSCs is related to specific adhesion molecules (176).  In cases of GVDH, 
NK cells could have a negative effect on injected allogeneic MSCs, which threatenes the fate 
of the transplant (203).  Despite these in vitro observations, it is still unknown if NK cell-
mediated killing of allogeneic MSCs occurs when these MSCs used for therapy of the bone 
repair.  In summary, NK cell-mediated killing of allogeneic MSCs could be another mechanism 
causing the failure of therapeutic use of MSCs. 
Allogeneic and autologous %0 06&V ORDGHG RQ K\GUR[\DSDWLWH RU ȕ-tricalcium 
phosphate scaffolds then implanted in femoral defect in dogs or tibia defect in mini pigs or 
radius injury in rabbits, showed similar extent of the bone growth without eliciting an immune 
response (204-206).  Additionally, an implantation of adipose±derived MSCs loaded on matrix 
into ulnar defect in rabbits or added to fibrin glue to fill the mandible defect in rats showed 
positive bone healing results comparable to that using autologous MSCs (207, 208).  Seeding 
of DOORJHQHLF06&VLQȕ-tricalcium phosphate scaffolds implanted in dogs has been shown to 
elicit an inflammatory response, measured by increase of the number of T lymphocytes, similar 
to that induced by autologous MSCs (209).  These observations indicate that the interactions 
between allogeneic MSCs and recipient immune cells could be avoided if these MSCs are 
loaded on mineralised scaffolds thus minimizing their accessibility to host immune cells. 
 
 
VIII. Conclusions and future perspectives 
Osteoimmunology is an emerging discipline exploring the relationship between inflammation 
and bone biology and how inflammatory signals control bone healing.  Similar to the repair of 
muscle injuries and skin wounds where MSCs are involved in all stages of the repair (210), 
MSCs interact with various cells, cytokines and growth factors during the whole process of the 
bone fracture healing (211).  The effect of inflammation on the bone healing through interaction 
between MSCs and immune cells is complex.  As explained, inflammatory cells and cytokines 
prime MSCs towards immunomodulatory function while the excess activation of the same 
mediators can suppress the osteogenic differentiation of MSCs.  Furthermore, cytokines like 
IL-17 could promote or suppress osteogenesis via its dual effect on both osteoblasts and 
osteoclasts.  Therefore a fine balance between the functions of MSCs and inflammatory 
mediators and cells as well as between osteoclasts and osteoblasts exists and the disturbance in 
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these balances can lead to the complications of the bone repair such as delayed healing or 
fracture non-union.  
Whilst the suppression of inflammation is needed for MSC differentiation to proceed, 
inappropriate inflammatory-mediated priming of MSCs could lead to a failure in switching off 
the inflammatory signals and hence to impaired progression through the bone healing stages.  
The ultimate goal for using MSCs in cases of bone defect or fractures should not be only be as 
powerful osteogenic cells but also as immune mediators controlling the inflammatory stage of 
bone healing.  Indeed, several therapeutic approaches targeting inflammation in animal models 
of delayed healing have been shown successful outcomes (212).  The better understanding of 
MSC-immune cell interactions during the bone healing is therefore highly important in order 
to modulate MSC-based therapy and ultimately treat or prevent challenging cases of bone 
injuries. 
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Figure legends  
 
Figure 1 Cells involved during three stages of secondary bone healing 
MSCs are involved in the three phases of bone healing.  Macrophages similarly play various 
roles during the whole process.  Neutrophils and NK cells are known to be involved only during 
inflammatory phase.  In contrast, B and T lymphocytes are involved in inflammatory phase 
then during late repair and early remodelling phase.  Chondroblasts are specifically active 
during repair phase of the secondary healing.  Osteoblasts are involved in the repair phase of 
the primary healing and in the remodelling phase of either secondary or primary healing.  In 
comparison, osteoclasts are contributed in both inflammatory and remodelling phases of the 
repair. 
 
Figure 2 Interactions between MSCs, immune cells and bone cells during bone healing 
During inflammatory phase, immune cells induce the proliferation of MSCs and prime them. 
MSCs in turn, control inflammatory response.  Additionally, immune cells stimulate 
osteoclasts to remove bone debris.  During repair phase, MSCs differentiate into chondroblasts 
(secondary healing), which then mature into chondrocytes that form cartilaginous callus. With 
help of immune cells, cartilaginous callus converts into bone callus. Finally, balance between 
osteoblasts and osteoclasts help remodelling of bone callus into lamellar bone. 
 
Figure 3 The magnitude of inflammation affects the fate of bone healing via interactions 
with MSCs 
A short acute inflammatory phase carried out by active cells and cytokines, helps to recruit and 
stimulate the proliferation of MSCs.  Additionally, this inflammatory response stimulates the 
immunosuppressive effects of MSCs ending the inflammatory phase and progressing into 
normal repair phase.  In contrast, uncontrolled or chronic/exaggerated inflammatory phase is 
associated with excessively activated cells and cytokines.  These factors lead to inhibition of 
proliferation and osteogenic differentiation of MSCs causing an impairment of bone healing. 
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Table 1: The role of immune cells during the bone healing 
 
Immune Cell Role Phase Reference 
Neutrophils Eliminate microbial infection. 
Remove damaged tissue and 
debris 
Inflammatory 
Inflammatory 
(30) 
(27) 
Macrophages Production of BMPs. 
Production of Oncostatin M that 
stimulates MSC osteogenesis. 
Exosomes stimulates MSC 
osteogenesis. 
Deposition of collagen I. 
Transition of cartilaginous callus 
into bone callus. 
Inflammatory/Repair 
Inflammatory/Repair 
 
Inflammatory/Repair 
 
Repair 
Repair 
(35, 36)   
(37, 38) 
 
(39) 
 
(126, 127) 
(120, 121)    
NK cells Priming of immunomodulatory 
function of MSCs. 
Migration of MSCs.  
Production of RANKL, which 
induces osteoclast formation. 
Inflammatory 
 
Inflammatory 
Inflammatory 
 
(42) 
 
(46) 
(47)  
 
ILCs IL-17: Osteoblast maturation, 
and osteogenesis of MSCs. 
IL-22: MSCs proliferation and 
differentiation. 
Late inflammatory? 
 
Late inflammatory? 
(63)  
 
(64)   
 
T lymphocytes  Priming of immunomodulatory 
function of MSCs. 
Stimulate osteogenesis of MSCs. 
Production of RANKL, which 
induces osteoclast formation. 
Transition of cartilaginous callus 
into bone callus. 
Inflammatory 
 
Inflammatory 
Inflammatory 
 
Late repair 
 
(34) 
 
(71) 
(69, 70) 
 
(44, 45) 
Th17 cells Stimulate MSC osteogenesis. 
Induce osteoblast maturation. 
Transition of cartilaginous callus 
into bone callus. 
Induce osteoclast generation. 
Inflammatory 
Repair 
Repair 
Remodelling 
 
(63)  
(63) 
(138)   
(154) 
T reg 
lymphocytes 
Decrease immunosuppressive 
effect of MSCs 
Stimulate bone healing 
Inflammatory 
 
Repair 
(73)   
 
(72) 
B 
lymphocytes 
Stimulate osteoclastogenesis.  
Transition of cartilaginous callus 
into bone callus. 
Induce death of osteoclasts. 
Inflammatory 
Late repair 
Early remodelling 
(74) 
(75) 
(44, 45) 
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Table 2: The role of soluble factors during the bone healing 
 
 
 
 
 
 
 
 
 
 
 
 
 
Soluble factor Role Phase Reference 
TNF-Į Migration of MSCs. 
Prime MSCs for 
immunosuppression. 
Regulate the functions of 
osteoclasts and osteoblasts 
Inflammatory 
Inflammatory 
Remodelling 
(87) 
(90)  
(44, 45)  
IFN-Ȗ Stimulate proliferation of MSCs. 
Prime MSCs for 
immunosuppression.  
Inflammatory 
Inflammatory 
(92)  
(92) 
IL-1 Prime MSCs for 
immunosuppression.  
Inflammatory (91) 
IL-17 Prime MSCs for 
immunosuppression. 
Stimulate the proliferation and 
osteogenesis of MSCs. 
Promote osteoblast maturation. 
Induce osteoclastogenesis. 
Inflammatory 
Repair  
 
Remodelling 
Remodelling 
(95)  
(63) 
 
(63) 
(153) 
IL-22 The migration, proliferation and 
differentiation of MSCs 
Inflammatory  (64) 
CCR2 Increase vasculature. 
Recruit macrophages. 
Inflammatory 
And repair 
(31) 
TGF-ȕ Suppress immune response.  
Enhance osteogenic differentiation 
of MSCs. 
Inflammatory 
Repair 
(96, 97) 
(96) 
BMPs Enhance proliferation and 
osteogenic differentiation of 
MSCs.  
Promote osteoblast maturation. 
inflammatory/Repair  
 
Repair 
(157, 158) 
 
(159-161) 
SDF-1 Recruitment of MSCs Inflammatory (83) 
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